Like most organizations around the world, BioStem has been closely monitoring the COVID-19 pandemic and its impact on patients, healthcare professionals, and our community. We continue to monitor and respond to this rapidly changing situation based on updates and recommendations from the CDC and local health officials, so please visit this page for updates.
To reach us directly with any questions, please email firstname.lastname@example.org
One of our top priorities is to ensure the health and safety of our employees. To reduce the risk of virus transmission, we are taking measures to maximize "social distancing" by asking all BioStem employees to work from home if they are able, minimize non-essential travel, and leverage digital tools and platforms in place of face-to-face meetings.
BioStem's manufacturing facility in Pompano Beach, Fl., remains open and operational. As an added precaution, BioStem has limited access to our manufacturing facilities to essential personnel only, to reduce the risk of transmission. The entire BioStem team remains fully committed to the delivery of our proprietary perinatal tissue allografts to clinics and doctors.
BioStem works with a network of partners to collect the birth tissue needed to manufacture our perinatal tissue allografts.
Our collection partners have taken additional measures to maintain patient safety in response to COVID‐19. These measures include: screening incoming patients regarding recent travel, and pre-screening to assess patients' health and well-being.